Abstract
Treatment for hepatitis C virus infection is limited in patients not responding to traditional therapy. Amantadine is effective for influenza infections and has been studied in patients with hepatitis C. Our aim was to determine the efficacy and safety of amantadine and to study the viral kinetics following amantadine therapy. Twelve patients with detectable HCV antibodies received amantadine 100 mg, orally twice daily. Serial HCV RNA and ALT blood samples were drawn and adverse effects were evaluated. Mean HCV RNA levels did not decrease in the first 24 hr of amantadine therapy but did decline significantly by day 3, only to rebound by day 7. All HCV RNA levels remained detectable throughout therapy and were not different from baseline values. Thirty-three percent of the patients obtained normal ALT levels after the first 24 hr of treatment and levels remained within normal range throughout the study period. More than a third of the patients discontinued therapy due to severe adverse effects occurring within one to three months after initiating treatment. In conclusion, although amantadine therapy alone was not effective, it should be considered as an adjunctive form of therapy along with interferon and ribavirin.
Similar content being viewed by others
REFERENCES
Seeff LB: Natural history of hepatitis C. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132:299–300, 2000
McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485–1492, 1998
Dusheiko G: Side effects of alpha interferon in chronic hepatitis C. Hepatology 26(3 suppl 1):112S–121S, 1997
Skehel JJ, Hay AJ, Armstrong JA: On the mechanism of inhibition of influenza virus replication by amantadine hydrochloride. J Gen Virol 38:97–110, 1978
Smith JP: Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 42:1681–1687, 1997
Gretch DR: Diagnostic tests for hepatitis C. Hepatology 26(suppl 1):43S–47S, 1997
Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y: Typing hepatitis C virus by polymerase chain reaction with type specific primers application to clinical surveys and tracing infection sources. J Gen Virol 73:673–679, 1992
Tabone M, Ercole E, Zaffino C, Sallio Bruno F, Pera A, Bonino F: Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients. Ital J Gastroenterol Hepatol 30:611–613, 1998
Goff JS, Reveille M. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 45:1389–1391, 2000
Senturk H, Mert A, Akdogan M, Tabak F, Basaran G, Turkoglu S, Ozbay G, Badur S: Amantadine monotherapy of chronic hepatitis C patients infected with genotype 1b. Scand J Infect Dis 32:575–576, 2000
Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ: Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 26:226–231, 1997
Martin J, Navas S, Fernandez M, Rico M, Pardo M, Quiroga JA, Zahm F, Carreno V. In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virusinfected patients. Antiviral Res 42:59–70, 1999
Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103–107, 1998
D'Agostini C, Palamara AT, Favalli C, Sivilia M, Febbraro G, Bue C, Garaci E: Efficacy of combination therapy with amantadine, thymosin alpha 1 and alpha/beta interferon in mice infected with influenza A virus. Int J Immunopharmacol 18:95–102, 1996
Hayden FG: Combination antiviral therapy for respiratory virus infections. Antiviral Res 29:45–48, 1996
Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L: Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 32:630–634, 2000
Endo Pharmaceuticals: Amantadine package insert. Chadds Ford, Pennsylvania, Endo Pharmaceuticals Inc., February 1998
Parkers JD, Marsden CD, Price P: Amantadine-induced heartfailure. Lancet 1:904, 1977
Vale JA, Maclean KS: Amantadine-induced heart-failure. Lancet 1:548, 1977
Stange KC, Little DW, Blatnik B: Adverse reactions to amantadine prophylaxis of influenza in a retirement home. J Am Geriatr Soc 39:700–705, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chan, J., O'Riordan, K. & Wiley, T.E. Amantadine's Viral Kinetics in Chronic Hepatitis C Infection. Dig Dis Sci 47, 438–442 (2002). https://doi.org/10.1023/A:1013703013053
Issue Date:
DOI: https://doi.org/10.1023/A:1013703013053